Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: A prospective cohort study

BMC Public Health

Volumn 12, Issue 1, 2012, Pages

  Goswami, Neela D ^a   Gadkowski, Lara Beth ^a   Piedrahita, Carla ^b   Bissette, Deborah ^b   Ahearn, Marshall Alex ^c   Blain, Michela Lm ^c   Stbye, Truls ^c   Saukkonen, Jussi ^d   Stout, Jason E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Wake County Human Services   (United States)

^c DUKE UNIVERSITY   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Attitude; Compliance; Geographic; LTBI

Indexed keywords

ADULT; AGED; ARTICLE; FEMALE; HUMAN; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; PATIENT ATTITUDE; PROSPECTIVE STUDY; QUALITATIVE RESEARCH; QUESTIONNAIRE; RISK FACTOR; SOCIOECONOMICS; STATISTICS; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; QUALITATIVE RESEARCH; QUESTIONNAIRES; RISK FACTORS; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84862493579     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-12-468     Document Type: Article

References (24)

1. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC, Ann Intern Med 2002 137 8 640 647 12379063 (Pubitemid 35176096)
2. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D, Int J Tuberc Lung Dis 2010 14 5 551 559 20392347
3. Latent TB infection treatment acceptance and completion in the United States and Canada. Horsburgh CR, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, Hughes S, Shrestha-Kuwahara R, Sterling TR, Wall K, et al. Chest 2010 137 2 401 409 10.1378/chest.09-0394 19793865
4. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW, Int J Tuberc Lung Dis 2008 12 11 1235 1254 18926033
5. 4months of rifampin compared with 9months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Ziakas PD, Mylonakis E, Clin Infect Dis 2009 49 12 1883 1889 10.1086/647944 19911936
6. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, et al. JAMA 2000 283 11 1445 1450 10.1001/jama.283.11.1445 10732934
7. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, Contave M, Johnson M, Davis H, Geiter L, et al. Lancet 1998 351 9105 786 792 10.1016/S0140-6736(97)06532-X 9519950 (Pubitemid 28112340)
8. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. CfDCaPCAT S, MMWR Morb Mortal Wkly Rep 2003 52 31 735 739 12904741
9. Treatment of latent tuberculosis infection: an update. Lobue P, Menzies D, Respirology 2010 15 4 603 622 10.1111/j.1440-1843.2010.01751.x 20409026
10. Sterling TR BA, Shang N, Bliven-Sizemore E, Chaisson RE, Gordin F, Hackman J, Hamilton CD, Horsburgh CR, Kerrigan A, Menzies D, Scott N, Villarino ME, and the Tuberculosis Trials Consortium, The PREVENT TB Study of 3 months of once-weekly rifapentine plus INH vs. 9 months of daily INH for treatment of latent TB infection: first report of results of a multi-center, randomized clinical trial In: 41st Union World Conference on Lung Health: November 2010, Berlin, Germany 2010
11. Use of isoniazid for latent tuberculosis infection in a public health clinic. LoBue PA, Moser KS, Am J Respir Crit Care Med 2003 168 4 443 447 10.1164/rccm.200303-390OC 12746255 (Pubitemid 37046873)
12. Predictors of failure to complete treatment for latent tuberculosis infection. Parsyan AE, Saukkonen J, Barry MA, Sharnprapai S, Horsburgh CR, J Infect 2007 54 3 262 266 10.1016/j.jinf.2006.04.010 16772095 (Pubitemid 46238167)
13. Factors associated with the treatment of latent tuberculosis infection among health-care workers at a midwestern teaching hospital. Shukla SJ, Warren DK, Woeltje KF, Gruber CA, Fraser VJ, Chest 2002 122 5 1609 1614 10.1378/chest.122.5.1609 12426260 (Pubitemid 35366071)
14. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Li J, Munsiff SS, Tarantino T, Dorsinville M, Int J Infect Dis 2010 14 4 292 e297 10.1016/j.ijid.2009.05.007 19656705
15. Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil. Machado A, Finkmoore B, Emodi K, Takenami I, Barbosa T, Tavares M, Reis MG, Arruda S, Riley LW, Int J Tuberc Lung Dis 2009 13 6 719 725 19460247
16. Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, Saukkonen JJ, Am J Respir Crit Care Med 2006 174 6 717 721 10.1164/rccm.200510- 1667OC 16809632 (Pubitemid 44395341)
17. Medication adherence in hispanics to latent tuberculosis treatment: a literature review. Zuniga JA, J Immigr Minor Health 2010 14 1 23 9
18. Tuberculosis knowledge, attitudes, and beliefs among North Carolinians at increased risk of infection. West EL, Gadkowski LB, Ostbye T, Piedrahita C, Stout JE, N C Med J 2008 69 1 14 20 18429559
19. Health care workers and the initiation of treatment for latent tuberculosis infection. Gershon AS, McGeer A, Bayoumi AM, Raboud J, Yang J, Clin Infect Dis 2004 39 5 667 672 10.1086/422995 15356781 (Pubitemid 39180439)
20. Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain. Diaz A, Diez M, Bleda MJ, Aldamiz M, Camafort M, Camino X, Cepeda C, Costa A, Ferrero O, Geijo P, et al. BMC Infect Dis 2010 10 267 10.1186/1471-2334-10-267 20840743
21. Formulation and evaluation of antisebum secretion effects of sea buckthorn w/o emulsion. Akhtar N, Khan BA, Mahmood T, Parveen R, Qayum M, Anwar M, Shahiq Uz Z, Farooq M, J Pharm Bioallied Sci 2010 2 1 13 17 10.4103/0975-7406.62698 21814424
22. Incentives vs outreach workers for latent tuberculosis treatment in drug users. Malotte CK, Hollingshead JR, Larro M, Am J Prev Med 2001 20 2 103 107 10.1016/S0749-3797(00)00283-X 11165450 (Pubitemid 32106944)
23. An incentive in tuberculosis preventive therapy for an inner city population. Mangura BT, Passannante MR, Reichman LB, Int J Tuberc Lung Dis 1997 1 6 576 578 9487458 (Pubitemid 127509905)
24. Directly observed therapy for treating tuberculosis. Volmink J, Garner P, Cochrane Database Syst Rev 2007 4 D003343 17943789